Background
Depression is the most frequently occurring psychiatric disorder [
1] with 1 in 10 adults reporting depression [
2]. Depression has been shown to have a wide variety of adverse health outcomes including poorer physical and social functioning, and decreased quality of life [
3‐
5] as well as an increase in morbidity and mortality [
6‐
8]. Understanding the link between depression and environmental factors that may influence its occurrence, symptom presentation, and severity, may have a significant impact on our understanding of the biological mechanisms underlying depression and its treatment. Past research has shown relationships between depression and environmental factors, such as natural sour gas containing H
2S [
9] and pesticides [
10]. Another naturally occurring substance that has been related to depression is selenium.
Past research has shown that selenoproteins are essential for numerous biological functions [
11], many of which are thought to be related to depression. Depression is thought to be unpinned by multiple pathways, such as inflammation, oxidative and nitrosative stress, as well as a decrease in antioxidant levels [
12‐
14]. Selenium, in the form of Selenoprotein P, protects the brain against oxidative damage [
15] and is involved in the regulation of the inflammatory response [
11]. Additionally selenium, an antioxidant and an essential component in the glutathione peroxidase system, protects lipids in polyunsaturated membranes from oxidative degradation. Depression is often associated with lower levels of antioxidants, such as glutathione and GPx, glutathione peroxidase enzyme [
16,
17]. These findings suggest that selenium may be protective against depression, and selenium supplementation may have the potential to alleviate the symptoms of depression. However, research investigating the relationship between selenium and depression has yielded inconsistent findings. Low selenium concentrations have been related to increased incidence of many human diseases including depression [
18‐
20]. Rayman et al. [
21] failed to identify any benefit in mood or quality of life in a sample of elderly participants. Prenatal selenium supplementation has been linked to increased serum selenium levels as well as decreased risk for postpartum depression [
22]. Pasco et al. [
23] found that lower dietary selenium was related to a new diagnosis of major depression. Recently, Gao et al. [
24] found that higher selenium were associated with lower GDS scores; however this effect was no longer significant when cognitive functioning was added to the model. This finding is interesting because it suggests that the link between selenium and depression may be impacted by individual factors, such as genetic variants that may impact the selenium levels in the body.
Selenium also plays a key role in proper functioning of the glutathione peroxidase system, which has been linked to depression. The glutathione peroxidase enzyme (GPx) is expressed in lower amounts among depressed patients, and GPx activity has been linked to depressed mood and autonomic symptoms [
25]. Because functional variants have been identified within glutathione peroxidase genes, genetic variation within the glutathione peroxidase pathway is an important consideration when examining selenium-health status links. In particular, the Pro198Leu polymorphism of the glutathione peroxidase 1 (GPX1) gene (rs1050454) has received a great deal of attention recently in the literature [
26]. This polymorphism contains a c.599C>T SNP, which is also referred to as rs1050450. The single nucleotide polymorphism (SNP) likely affects the activity of variant proteins [
27]. The T allele of the rs1050450 GPX1 SNP has been associated with bladder, lung, and breast cancers, intracerebral hemorrhage [
28], metabolic syndrome [
29], and coronary artery disease [
30]. It is functional in humans and impacts the response of GPX1 activity to selenium [
31]. Genetic polymorphisms of the GPX1 gene have been shown to be related to tumor susceptibility [
32], blood selenium levels associated with supplementation [
33], and other health conditions. However, to date, we are aware of no studies that have examined the impact of GPX1 polymorphisms on the selenium- depression link.
The current study was designed to (a) study the link between groundwater selenium levels and depressive symptoms, (b) determine if the Pro198Leu GPX1 directly impact depression risk, and (c) determine if the Pro198Leu polymorphisms of the GPX1 gene impact these findings. It was hypothesized that higher groundwater selenium would be protective against depressive symptoms. No specific a priori hypotheses were made regarding the Pro198Leu polymorphism given that this is the first study to examine the role of this genetic variant in depression.
Results
The mean age and education of the sample was 61.49 (sd = 12.70; range = 40-96) and 10.76 (sd = 4.37; range = 0-20), respectively. Mean GIS-based selenium concentration was 17.70 μg/L (sd = 10.66; range = 3.96-56.32). Seventy-seven percent of the sample was interviewed in English and 33% in Spanish; 88% of the sample self-reported their race as White, and 38% reported their ethnicity as Mexican American. Mean GDS-30 score of the sample was 10.49 (sd = 5.07; range = 0-26). Demographic characteristics of the sample are presented in Table
1.
Table 1
Demographic characteristics
Age | 61.45 (12.70) | 40-96 |
Education | 10.76 (4.37) | 0-20 |
GIS-selenium (μg/L) | 17.70 (10.67) | 3.96-56.32 |
GDS Total | 10.49 (5.07) | 0-26 |
GDS Dysphoria | 3.31 (2.44) | 0-11 |
GDS Meaninglessness | 2.24 (1.43) | 0-7 |
GDS Apathy | 2.87 (1.42) | 0-6 |
GDS Cognitive Impairment | 1.87 (1.19) | 0-6 |
GPX1 Polymorphism (%) | | |
CC | 46 | |
CT | 48 | |
TT | 6 | |
Selenium concentrations were found to be significantly and negatively related to all GDS scores. Specifically, higher selenium levels were significantly related to lower scores in the Total GDS-30 scores (β = -0.34, p < 0.001), explaining 11% of the variance. Higher selenium was also related to a decrease in factor scores of Dysphoria (β = -0.23, p < 0.001), explaining 5% of the variance, Meaninglessness (β = -0.42, p < 0.001), explaining 17% of the variance, and Apathy (β = -0.30, p < 0.001), explaining 9% of the variance. Higher selenium concentration was statistically a significant predictor of lower scores on the subfactor of Cognitive Impairment (β = -0.11, p = 0.01), but only accounted for 1% of the variance. The results of the regression analysis can be found in Table
2. Higher selenium concentration was also associated with a significantly lower risk of depression, with B = -0.06 (SE = 0.01), Wald (df = 1) = 37.25, p < 0.001, and OR = 0.94 (95% CI = 0.92-0.96).
Table 2
Linear regression results
GDS Total | −0.16 (0.02) | −8.21 | 0.000 | 11% |
GDS Dysphoria | −0.05 (0.01) | −5.24 | 0.000 | 5% |
GDS Meaninglessness | −0.06 (0.006) | −10.31 | 0.000 | 17% |
GDS Apathy | −0.04 (0.006) | −7.11 | 0.000 | 9% |
GDS Cognitive Impairment | −0.13 (0.005) | −2.53 | 0.012 | 1% |
The link between depression and GPX1 polymorphisms was strongest for CC (homozygous wild type) and TT (homozygous mutant type) carriers, with the greatest impact being for TT individuals as shown in Table
3. The TT polymorphism was the least frequent in the sample; however, for TT individuals, selenium concentrations accounted for 26% of the variance in GDS Total Score, 13% of the variance in Dysphoria, 37% of the variance in Meaninglessness, and 19% of the variance in Apathy. For the CC polymorphism, selenium concentrations accounted for 15% of the variance in total score, 9% of the variance in Dysphoria, 22% of the variance in Meaninglessness, and 14% of the variance in Apathy. The amount of variance for CT polymorphism was relatively small.
Table 3
Linear Regression Results by GPX1 Allele
CC (n = 221) | | | | | |
GDS Total | −0.18 (0.03) | −6.40 | <0.001 | 21% | 15% |
GDS Dysphoria | −0.05 (0.02) | −3.24 | 0.001 | 9% | 4% |
GDS Meaninglessness | −0.06 (0.007) | −8.04 | <0.000 | 24% | 22% |
GDS Apathy | −0.05 (0.008) | −6.10 | <0.000 | 18% | 13% |
GDS Cognitive Impairment | −0.02 (0.007) | −2.96 | 0.003 | 7% | 5% |
CT (n = 208) | | | | | |
GDS Total | −0.13 (0.04) | −3.58 | <0.001 | 10% | 6% |
GDS Dysphoria | −0.05 (0.02) | −2.99 | 0.003 | 9% | 4% |
GDS Meaninglessness | −0.05 (0.01) | −4.68 | <0.001 | 12% | 9% |
GDS Apathy | −0.03 (0.01) | −2.74 | 0.007 | 3% | 3% |
GDS Cognitive Impairment | 0.00 (0.008) | −0.05 | 0.96 | 2% | 0% |
TT (n = 33) | | | | | |
GDS Total | −0.27 (0.07) | −3.78 | <0.001 | 40% | 26% |
GDS Dysphoria | −0.08 (0.04) | −2.27 | 0.03 | 21% | 13% |
GDS Meaninglessness | −0.11 (0.2) | −5.11 | <0.000 | 53% | 37% |
GDS Apathy | −0.06 (0.02) | −2.81 | 0.009 | 28% | 19% |
GDS Cognitive Impairment | −0.02 (0.3) | −0.73 | 0.47 | 3% | 2% |
Next, we examined the impact of the GPX1 Pro198Leu polymorphism on the findings. First, we sought to determine if homozygous carriage of the C allele was associated with depression status (GDS ≥ 10 = depressed), compared to T allele carriers (CT plus TT; TT was not analyzed separately due to sample size). Logistic regression was conducted with depressed status as the outcome variable and GPX1 polymorphism (CC versus CT) as a categorical predictor variable. Sixty-six percent of CC homozygotes were depressed compared to 57% for T allele carriers; therefore, homozygous carriage of the C allele was associated with a significantly increased risk of depression (B = 0.50, SE = 0.19, Wald (df = 1) = 6.88, p = 0.009, and OR = 1.65 (95% CI = 1.14-2.40). Next, a linear regression model was created to examine the gene-dose effect of GPX1 C versus T (CC = 2, CT = 1, TT = 0) alleles on depression scores (GDS total score). With age, gender, education, and test language entered as covariates, the increasing presence of the T allele was associated with significantly higher GDS scores (B = 0.94, SE = 0.35, t = 2.69, and p = 0.008). Lastly, we re-ran our regression analyses examining the link between selenium concentrations and GDS scores (total and subfactors) after stratification of the sample on genotype at the GPX1 Pro198Leu polymorphism. The link between selenium levels and depression was strongest among CC and TT, as compared to CT individuals. The TT polymorphism was the least frequent in the sample. Of note, in regression analysis of groundwater selenium levels on depression risk, models that included Pro198Leu genotype along with age, gender, education, and language of test administration accounted for more variance (70%) than those that did not include genotypic status (50%). For CC polymorphism, selenium concentrations alone accounted for 15% of the variance in total score, 9% of the variance in dysphoria, 22% of the variance in meaninglessness, and 14% of the variance in apathy, which was more variance accounted for than found by covariates. The amount of variance for CT polymorphism was relatively small. See Table
3.
Therefore, these findings point to a gene-environment interaction, which is supported by the gene-dose findings.
Discussions and conclusions
In the past three decades, selenium has been found to be essential to various aspects of health [
47]. It has been found to play a role in prevention of cancer and cardiovascular disease as well as in regulating mood [
20]. Exposure to environmental factors, such as selenium, can also play a role in depression and anxiety states. Past research has shown that low selenium concentrations were related to depression status and other negative affective states [
18,
20]. In addition, studies have indicated that selenium may be useful in preventing postpartum depression [
22].
In the current study, higher groundwater selenium levels were associated with lower scores on the Geriatric Depression Scale. This finding is consistent with past research indicating that low selenium status is related to increased incidence of depression and other negative affective states [
18,
20]. In addition to the decrease in total depression scores, higher selenium levels were specifically related to a decrease in symptoms of Dysphoria, Meaninglessness, and Apathy, indicating that selenium may have an impact on particular types of depressive manifestations. It is interesting to note that selenium concentrations were only minimally related to the cognitive impairment subscale, as we have previously shown selenium to be selectively protective of memory functioning [
36]. This suggests that, despite the potential role of selenium concentrations in preserving cognitive function, depressive symptoms related to thoughts of cognitive dysfunction appear to be unrelated and may be related to the concept of insight.
This is the first study to examine residential groundwater selenium levels and depression. A myriad of factors determine the chemical make-up of groundwater in a given area, and it is important to be cognizant of the potential health impacts from such substances. Research on groundwater and its implications on human health can have profound implications in the realms of public health and policy. Additionally, results obtained by groundwater research could prove to be the impetus for the formation or reformation of population-based prevention strategies concerning groundwater safety and exposure. This study was conducted in a rural agricultural area where higher concentrations of groundwater selenium are typically found. Aligning with this, the mean selenium level in this study was 17.70 μg/L, whereas the national average is 10 μg/L [
48].
The protective impact of selenium on mental health fits with its biological activity and is supported by both animal model and human research. Selenium, a main constituent of neuronal selenoproteins, may be particularly important for sustaining healthy cerebral function [
47] through its key role in protection against oxidative damage [
15,
20,
49]. Oxidative damage is a key biological mechanism in depression pathophysiology, and many anti-depressants, like fluoxetine [
50] and venlafaxine [
51], reduce oxidative damage. Another possible mechanism of action is through selenium’s impact on brain-derived neurotrophic factor (BDNF), which has been linked to depression and found to be decreased in selenium deficient rats [
52]. Additionally, depression is also associated with lower antioxidant levels. Research has suggested that antioxidant deficiency found in depression may predispose individuals to greater inflammatory and oxidative and nitrosative responses [
13], which may contribute to the protective effects of selenium against depression.
Ours is the first study to directly examine the link between the GPX1 Pro198Leu polymorphism and depressive risk as well as its impact on the selenium-depression link. Our findings point to gene-environment interaction, which is supported by the gene-dose impact. Specifically, the C allele of the GPX1 polymorphism was associated with significantly increased risk of depression in a dose-dependent manner (i.e. CC > CT > TT). Additionally, the impact of environmental selenium concentrations on depression scores was stronger for the CC than CT group. The TT group showed a substantial impact in the expected direction, but due to the small sample number of TT homozygotes, these results must be replicated. It is also important to note the differences in effect sizes for selenium on depression observed in each genotypic group. Among CC homozygotes, the majority of variance accounted for in GDS scores was from selenium concentrations with age, gender, education, and language of test administration contributing less to GDS scores. Among the TT group, the amount of variance accounted for by selenium concentrations alone was substantial; however, covariates in the model also accounted for a larger portion of the variance. Future work is needed to delve more thoroughly into this gene-environment interaction as well as the dose-response impact of the C allele of the GPX1 polymorphism on risk for depression. Additional work is also required to examine other potential genes of interest. For example, Galecki and colleagues [
53] identified polymorphisms of the NOS2A gene, which are important in the nitric oxide pathways, as related to recurrent depression. Given that selenium (i.e. selenoproteins) is involved in the nitric oxide pathway as well, NOS2A and other genes relevant to pathways linked to selenium should be examined. It is likely that more sophisticated bioinformatic analyses will be necessary to disentangle these multi-level gene-(biological mechanism) – environmental exposure – depression interactions.
These results point towards possible pharmacogenetic implications of the Pro198Leu GPX1 polymorphism. Specifically, in our sample, CC homozygotes had significantly increased risk for depression; however, selenium was also most powerfully protective against depression and depressive symptoms among those particular carriers. Therefore, future research looking at the therapeutic impact of selenium on depression should examine this genotype. Additionally, previously conducted clinical trials of anti-depressant medications with stored DNA (or previously conducted genetic analyses) can determine if Pro198Leu GPX1 genotype predicts optimal treatment response. Lastly, the Pro198Leu GPX1 polymorphism may be useful for identifying those individuals most likely to benefit from anti-depressant medications in new clinical trials.
There are limitations to the current study. One is the GIS-based estimate of selenium concentration rather than direct measurement. However, our prior work, as well as that of others, has shown that GIS-based methods are valid ways for estimating environmental exposures. The current findings should be replicated using direct selenium measurement. The cross-sectional nature of the study is another limitation; however, our prior work has shown selenium to be preventative of cognitive decline prospectively in a subset of this cohort [
30]. Future studies will examine the protective impact of selenium concentrations on both depression and cognitive decline as future waves become available. The current study also has several strengths. Specifically, this is the first study to examine this link in such detail (i.e. depressive symptoms rather than only global scores) as well as look at this topic among rural-dwelling adults and elders. This is also the first study to examine the impact of genetic variation within GPX1 on depression risk as well as the selenium-depression link. Taken together, these results point to the need for continued work in the area, as selenium may provide a therapeutic target for preventative strategies aimed at reducing depressive incidence rates in vulnerable populations. Additional work is also needed to determine the pharmacogenetic implications of the Pro198Leu GPX1 polymorphism in depression therapies.
Competing interests
The authors declare no competing financial interests. This work was funded in part by the Science To Achieve Results (STAR) Program of the U.S. Environmental Protection Agency (EPA) grant # RD83479401 (O’Bryant, PI), National Institute on Minority Health and Health Disparities (NIMHD) award #L60MD001849 and the Hogg Foundation grant # JRG-040 (O’Bryant, PI).
Authors’ contributions
LJ: Designed the study, participated in data collection and analysis, and manuscript preparation. JP: Participated in data collection, entry, and manuscript preparation. CM: Participated in data collection and manuscript preparation. ME: Participated in data collection, and manuscript preparation. VB: Participated in data collection, analysis, and manuscript preparation. JH: Assisted in study design, data analysis, and manuscript preparation. RB: Assisted in study design, data analysis, and manuscript preparation. TC: Assisted in data analysis, and manuscript preparation. EH: Participated in manuscript preparation. SO: Designed the study, participated in data collection and analyses, and manuscript preparation. All authors have read and approved this manuscript.